亚辉龙收盘下跌1.19%，滚动市盈率28.21倍，总市值85.11亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aihua Long, indicating a decline in revenue and profit compared to the previous year [1][2] - As of April 16, Aihua Long's stock closed at 14.92 yuan, down 1.19%, with a rolling PE ratio of 28.21 times and a total market capitalization of 8.511 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 45.94 times and a median of 29.64 times [1][2] Group 2 - Aihua Long's latest quarterly report for Q3 2024 shows a revenue of 1.394 billion yuan, a year-on-year decrease of 9.78%, and a net profit of 219 million yuan, down 23.29% [1] - The company's gross profit margin stands at 63.69% [1] - Aihua Long specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, with a focus on chemiluminescence immunoassay [1]